The latest medical research on Gastroenterology

The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about gastroenterology gathered by our medical AI research bot.

The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.

Want more personalised results?

Request Access

A randomized controlled trial of an integrated alcohol reduction intervention in patients with hepatitis C infection.

Hepatology

Hepatitis C (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested c...

Economic and Healthcare Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States.

Hepatology

The paucity of data regarding the extent of Hepatitis delta virus (HDV) associated healthcare burden in the United States is an important obstacle ...

Tumour evolution in hepatocellular carcinoma.

Nat Rev Gastroenterol

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically develops on the background of chronic liver disease and is ...

DIVERSITY OF NEUROGENIC SMOOTH MUSCLE ELECTRICAL RHYTHMICITY IN MOUSE PROXIMAL COLON.

Am J Physiol

The mechanisms underlying electrical rhythmicity in smooth muscle of the proximal colon are incompletely understood. Our aim was to identify patter...

Reply: Alcohol and mortality in NAFLD: Is the cabernet causal or confounder?

Hepatology

We thank doctors Gow, Testro, Hey, and Sinclair for their interest in our study and for sharing their views on the potential benefits of alcohol. I...

Moderate alcohol use in fatty liver disease; don't throw the cabernet out with the bathwater.

Hepatology

We congratulate Dr Aberg and colleagues for a significant contribution to the literature on the important topic of moderate alcohol use in fatty li...

Endothelial Bmp2 knockout exacerbates hemochromatosis in Hfe knockout mice but not Bmp6 knockout mice.

Hepatology

Bone morphogenetic proteins BMP2 and BMP6 play key roles in systemic iron homeostasis by regulating production of the iron hormone hepcidin. HFE al...

Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.

Hepatology

Model of End-Stage Liver Disease (MELD) is used for clinical decision making and organ allocation for orthotopic liver transplantation (OLT) and wa...

An Open Label, Dose Escalation Study To Assess The Safety And Efficacy Of IL-22 Agonist F-652 In Patients With Alcoholic Hepatitis.

Hepatology

Interleukin-22 (IL-22) has beneficial effects on inflammation and impaired hepatic regeneration, that characterize AH. F-652 is a recombinant fusion protein of human IL-22 and IgG2-Fc.

To assess safety and efficacy signals of F-652 in patients with moderate and severe AH.

A phase-2 dose escalating study was carried out. F-652 (10, 30 or 45 μg/kg) administered on day-1 and 7 was tested in 3 patients each with moderate (MELD-scores:11-20) and severe AH (MELD-scores:21-28). Safety was defined by absence of serious adverse events (SAE) and efficacy was assessed by Lille score, changes in MELD score, and serum bilirubin and aminotransferases at days 28 and 42. Three independent propensity matched comparator patient cohorts were used. Plasma extracellular vesicles (EVs) and multiplex serum cytokines were measured to assess inflammation and hepatic regeneration.

18 patients (9 moderate and 9 severe AH) were enrolled, 66% male, mean age 48 years. The half-life of F-652 following the first dose was 61-85 hours. There were no SAE leading to discontinuation. MELD score, and serum aminotransferases decreased significantly at days 28 and 42 from baseline (p<0.05). Day-7 Lille score was ≤0.45 in 83% patients as compared with 6%,12%, and 56% among the comparator cohorts. EV counts decreased significantly at day-28 (p<0.013). Cytokine inflammatory markers were downregulated, and regeneration markers were upregulated at days 28 and 42.

F-652 is safe in doses up to 45 μg/kg and associated with high rate of improvement as determined by Lille and MELD scores, reductions in markers of inflammation and increases in markers of hepatic regeneration. This study supports the need for randomized placebo-controlled trials to test efficacy of F-652 in AH.

Interrogating host immunity to predict treatment response in inflammatory bowel disease.

Nat Rev Gastroenterol

IBD treatment is undergoing a transformation with an expanding repertoire of drugs targeting different aspects of the immune response. Three novel ...

The mechanosensor Transient Receptor Potential Vanilloid Member 4 (TRPV4) regulates mouse cholangiocyte secretion and bile formation.

Am J Physiol

Mechanosensitive signaling has emerged as a mechanism for the regulation of cholangiocyte transport and bile formation. The mechanical effect of fl...

Reply to "Does the HSD17B13 rs72613567 splice variant actually yield a new type of alternative splicing".

Hepatology

We appreciate Dr. Galmozzi's interest in our study and his insightful comments. Briefly, we recently discovered single nucleotide polymorphisms (SN...